<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="benefit in curing chikungunya (low-certainty evidence). The evidence for COVID-19" exact="infection" post="is rapidly evolving but at this stage we are"/>
 <result pre="were excluded. Participants Adults or children with a confirmed viral" exact="infection" post="were included. Intervention and comparator All participants (non-controlled studies)"/>
 <result pre="extracted from each included study: study design and location, viral" exact="infection" post="and diagnostic criteria, participant demographics, intervention and control groups"/>
 <result pre="risk of bias. Certainty of evidence was assessed for each" exact="infection" post="(only from randomized controlled trials, RCTs) according to the"/>
 <result pre="Fig.Â 2 . The results are discussed separately for each" exact="infection" post="and under each section; randomized clinical trials are discussed"/>
 <result pre="Chronic infections (HIV/HCV) are discussed first as the aim of" exact="treatment" post="is viral load suppression rather than cure. Details of"/>
 <result pre="all examining the role of HCQ and CQ in COVID-19" exact="infection" post="(TableÂ 3 ). Fig.Â 1 PRISMA flow diagram of"/>
 <result pre="without CQ and with CQ High risk of performance and" exact="detection" post="bias due to open-label designHigh risk of attrition bias"/>
 <result pre="HLA DRÂ +Â CD8 cells were significantly reduced with CQ" exact="treatment" post="(p 0.016) Small clinical trial with 3â€&quot;6 patients per"/>
 <result pre="single-blind, controlled study Patients with chronic active HCV (genotype 4)" exact="infection" post="with chronic hepatitis on liver biopsy but without decompensated"/>
 <result pre="biasâ€&quot;method of allocation concealment not clearHigh risk of performance or" exact="detection" post="biasâ€&quot;single-blind study designNo additional adverse events due to HCQ"/>
 <result pre="first 3Â days of fever and later confirmed with diagnostic" exact="testing" post="(NS1 antigen test and RT-PCR) Group 1: CQ 600"/>
 <result pre="study Patients with clinically suspected dengue, later confirmed with diagnostic" exact="testing" post="Group 1: CQ 600 mg (base) for 3Â days"/>
 <result pre="[30] Randomized, double-blind, placebo-controlled trial Patients with confirmed acute chikungunya" exact="infection" post="by RT-PCR and seroconversion between day 1 and 16"/>
 <result pre="clinical trial Adult patients with virologically confirmed (RT-PCR) mild COVID-19" exact="infection" post="Group 1: HCQ 400 mg/d for 5Â days plus"/>
 <result pre="non-randomized, controlled trial Adult patients with virologically confirmed (RT-PCR) COVID-19" exact="infection" post="as test groupSimilar patients treated at a different institution"/>
 <result pre="patients treated at a different institution or those refusing HCQ" exact="treatment" post="at the same institute Group 1: HCQ 600 mg/d"/>
 <result pre="mg/d for 10Â days (nÂ =Â 26)Group 2: no HCQ" exact="treatment" post="(nÂ =Â 16) Statistically significant rate of clearance of"/>
 <result pre="clinical trial Adult patients with virologically confirmed (RT-PCR) mild COVID-19" exact="infection" post="Group 1: HCQ 400 mg/d for 5Â days plus"/>
 <result pre="trial Adult patients with virologically confirmed (RT-PCR) mostly mild COVID-19" exact="infection" post="Group 1: HCQ 200 mg/d for 3Â days followed"/>
 <result pre="This was a non-peer reviewed preprintHigh risk of performance and" exact="detection" post="bias Huang etÂ al. China, 2020 [40] Randomized controlled"/>
 <result pre="trial (open label?) Adult patients with virologically confirmed (RT-PCR) COVID-19" exact="infection" post="Group 1: CQ 600 mg base/d for 10Â daysGroup"/>
 <result pre="study and, if not, there is a high risk of" exact="detection" post="and performance biasMethod of sample size calculation is unclear"/>
 <result pre="Randomized controlled double-blind study Adult patients with clinically suspected COVID-19" exact="infection" post="Group 1: CQ 1200 mg base/d for 10Â daysGroup"/>
 <result pre="Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquine for" exact="treatment" post="of COVID19: a randomized control trial NCT04303299 ClinicalTrials.gov New"/>
 <result pre="treatment of COVID19: a randomized control trial NCT04303299 ClinicalTrials.gov New" exact="treatment" post="for radical cure of dengue fever with antiviral and"/>
 <result pre="single-blind, randomized controlled clinical trial for chloroquine phosphate in the" exact="treatment" post="of novel coronavirus pneumonia (COVID-19) ChiCTR2000031204 Chinese Clinical Trials"/>
 <result pre="trial for favipiravir tablets combine with chloroquine phosphate in the" exact="treatment" post="of novel coronavirus pneumonia (COVID-19) ChiCTR2000030987 Chinese Clinical Trials"/>
 <result pre="Trials Registry Randomized controlled trial for chloroquine phosphate in the" exact="treatment" post="of novel coronavirus pneumonia (COVID-19) ChiCTR2000030718 Chinese Clinical Trials"/>
 <result pre="Clinical Trials Registry Clinical study of chloroquine phosphate in the" exact="treatment" post="of severe novel coronavirus pneumonia (COVID-19) ChiCTR2000029988 Chinese Clinical"/>
 <result pre="study for exploration of chloroquine phosphate aerosol inhalation in the" exact="treatment" post="of novel coronavirus pneumonia (COVID-19) ChiCTR2000029975 Chinese Clinical Trials"/>
 <result pre="single-blind, randomized, controlled clinical trial for chloroquine phosphate in the" exact="treatment" post="of novel coronavirus pneumonia 2019 (COVID-19) ChiCTR2000029939 Chinese Clinical"/>
 <result pre="Registry A single-arm clinical trial for chloroquine phosphate in the" exact="treatment" post="of novel coronavirus pneumonia 2019 (COVID-19) ChiCTR2000029935 Chinese Clinical"/>
 <result pre="with HCQ in the other study after 6Â months of" exact="treatment" post="[23], suggesting an immunomodulatory role of HCQ. HCQ was"/>
 <result pre="CQ. Hepatitis C Use of CQ or HCQ for HCV" exact="infection" post="has been evaluated in two RCTs, one a single-blinded"/>
 <result pre="these agents. Dengue Two studies had assessed CQ for dengue" exact="infection" post="(none assessed HCQ). A double-blind RCT (nÂ =Â 307)"/>
 <result pre="Chikungunya is a viral illness endemic in the tropics. Acute" exact="infection" post="mimics a viral flu and sometimes leads to a"/>
 <result pre="2006, enrolled 54 adult patients with virologically confirmed acute chikungunya" exact="infection" post="to receive either CQ (600 mg of base/day for"/>
 <result pre="controlled trial evaluated HCQ for this purpose after acute chikungunya" exact="infection" post="[33]. However, as HCQ was not â€˜repurposedâ€™ as an"/>
 <result pre="to receive HCQ 600 mg/d [35]. Twenty patients completed HCQ" exact="treatment" post="(six patients also received azithromycin) and all had radiological"/>
 <result pre="receive HCQ (400 mg/d for 5Â days) or no HCQ" exact="treatment" post="(31 in each group). The respiratory distress was not"/>
 <result pre="versus 11/12). However, on average, the lopinavir/ritonavir group had started" exact="treatment" post="later than those in the CQ group (2.5 versus"/>
 <result pre="in 31 patients in each group. The recruits had severe" exact="infection" post="at the time of enrolment as defined by tachycardia,"/>
 <result pre="evolving situation at the time of writing). The most researched" exact="infection" post="in this regard is HIV. However, mainstream antiretroviral treatment"/>
 <result pre="researched infection in this regard is HIV. However, mainstream antiretroviral" exact="treatment" post="in HIV is highly successful in viral load suppression,"/>
 <result pre="do such tests. The same can be said of HCV" exact="infection" post="where pan-genotypic direct-acting antiviral agents can now achieve &amp;gt;90%"/>
 <result pre="may have little or no effect in curing acute chikungunya" exact="infection" post="(low-certainty evidence) and this conclusion is supported by a"/>
 <result pre="most patients with COVID-19 (&amp;gt;95%) will recover after a mild" exact="infection" post="regardless of antiviral treatment. Therefore, the primary outcome assessed"/>
 <result pre="[38] the control group is said to have received â€˜standardâ€™" exact="treatment" post="which includes â€˜antivirals, antibiotics and steroids or immunoglobulinsâ€™. These"/>
 <result pre="terms of achieving negative viraemia by day 14 compared to" exact="treatment" post="with lopinavir and ritonavir [40]. The authors report faster"/>
 <result pre="stay with CQ, but on average the CQ group received" exact="treatment" post="at an earlier stage of the illness than the"/>
 <result pre="is good evidence that CQ is ineffective in curing dengue" exact="infection" post="or preventing dengue haemorrhagic fever. CQ also may not"/>
 <result pre="Res Commun323200426426815351731 3VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J22005 4De ClercqE.Potential antivirals and antiviral strategies"/>
 <result pre="Omega32018181321814130613818 10ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.Repurposing of the anti-malaria drug chloroquine for Zika virus" exact="treatment" post="and prophylaxisSci Rep72017 11AkpovwaH.Chloroquine could be used for the"/>
 <result pre="treatment and prophylaxisSci Rep72017 11AkpovwaH.Chloroquine could be used for the" exact="treatment" post="of filoviral infections and other viral infections that emerge"/>
 <result pre="on rating quality of evidence and strength of recommendationsBMJ336200892418436948 17SperberK.LouieM.KrausT.PronerJ.SapiraE.LinS.Hydroxychloroquine" exact="treatment" post="of patients with human immunodeficiency virus type 1Clin Ther1719956226368565026"/>
 <result pre="antiretroviral therapy-treated immunologic nonrespondersBlood11820113263327221576701 24PatonN.I.AboulhabJ.KarimF.Hydroxychloroquine, hydroxycarbamide, and didanosine as economic" exact="treatment" post="for HIV-1Lancet35920021667166812020529 25PeymaniP.GhavamiS.YeganehB.TabriziR.SabourS.GeramizadehB.Effect of chloroquine on some clinical and"/>
 <result pre="clinical and biochemical parameters in non-response chronic hepatitis C virus" exact="infection" post="patients: pilot clinical trialActa Biomed8720164653 26PeymaniP.YeganehB.SabourS.GeramizadehB.FattahiM.R.KeyvaniH.New use of an"/>
 <result pre="Med Virol8820162170217827183377 28TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.AÂ randomized controlled trial of chloroquine for the" exact="treatment" post="of dengue in Vietnamese adultsPLoS Negl Trop Dis42010 29BorgesM.C.CastroL.A.FonsecaB.A.Chloroquine"/>
 <result pre="improves dengue-related symptomsMem Inst Oswaldo Cruz108201359659923903975 30De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On chikungunya acute" exact="infection" post="and chloroquine treatmentVector Borne Zoonotic Dis8200883783918620511 31de LamballerieX.NinoveL.CharrelR.N.Antiviral treatment"/>
 <result pre="acute infection and chloroquine treatmentVector Borne Zoonotic Dis8200883783918620511 31de LamballerieX.NinoveL.CharrelR.N.Antiviral" exact="treatment" post="of chikungunya virus infectionInfect Disord Drug Targets9200910110419275698 32RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.Paradoxical effect"/>
 <result pre="chikungunya virus infectionInfect Disord Drug Targets9200910110419275698 32RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.Paradoxical effect of chloroquine" exact="treatment" post="in enhancing chikungunya virus infectionViruses102018 33RavindranV.AliasG.Efficacy of combination DMARD"/>
 <result pre="Province health commission of Guangdong Province for chloroquine in the" exact="treatment" post="of novel coronavirus pneumoniaExpert Consensus Chloroquine Phosphate Treat Novel"/>
 <result pre="Phosphate Treat Novel Coronavirus Pneumonia432020185188 35GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt"/>
 <result pre="J Antimicrob Agents202010594932205204 36Chen JunL.D.LiL.PingL.QingnianX.LuX.YunL.AÂ pilot study of hydroxychloroquine in" exact="treatment" post="of patients with common coronavirus disease-19 (COVID-19)JÂ Zhejian Univ492020"/>
 <result pre="Netw Open32020e208857 42SpenglerU.Direct antiviral agents (DAAs)â€&quot;a new age in the" exact="treatment" post="of hepatitis C virus infectionPharmacol Ther183201811812629024739"/>
</results>
